Purpose or Objective: Owing to legitimate fears concerning potentially devastating complications, the treatment of head and neck cancer in previously irradiated patient has been based on surgery for the best cases and chemotherapy for the inoperable ones. We review our series of 84 routinely re-(chemot)irradiated patients since 2000.
Material and Methods:
Patients : 84 consecutive patients, mean age 60.47, previously treated by radio(chemo)therapy with a median delay between the the two irradiations of 36.3 months have been treated. 54 patients with relapses and 30 patients presenting second cancers . The mean follow-up is 66.45 months. Methods : 42 patients were operated upon, (chemo)radiotherapy being used postoperatively for poor prognostic factors. 42 inoperable patients have been treated exclusively by radiochemotherapy. Before 2007, patients were treated by 2D techniques then by IMRT. 44 received concomitant platinum-based chemotherapy, 23 cetuximab and 17 radiotherapy alone.
Results:
Results : median overall survival for the entire population is 19.61 months. Specific survival 23 months.Death causes : 40 the cancer itself, 9 patients complications et 11 other causes. Prognostic factors : age, sexe, performance status, Charlson score, location, type of resurgence (local, nodal or both), surgery, chemotherapy antecedents, type of concomitant treatment during the reirradiation, previous disabilities (tracheostomy, nasogastric tube) have been investigated. Only the type of resurgence is discriminant with a median survival time of 16.49 months for patients treated for a relapse and 32 months for those treated for a second cancer (Logrank p = 0.00464). Complications : 9 deceased : 1 carotid blowout (with evolutive tumor), 3 late pneumoniae (patient NED), 3 tumoral hemorrhages (evolutive tumors) and 2 unknown complications. Late sequellae: 10 radionecrosis (7 osteoradionecrosis), 7 persistant dysphagia, 8 long term fistulas.
Conclusion: Conclusion :
The survival in our series restricted to the second cancers is similar to that obtained in not previously irradiated patients and confirm some data of the literature. Thereby it is our belief that, if the acceptance of this strategy of treatment may merit further clinical trials for the relapsing tumor (however the results compare favorably with palliative chemotherapy), it becomes unethical not to give this chance for the second cancers in spite of the risk of severe complication.
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The role of adjuvant external beam radiation therapy for advanced papillary thyroid cancer C.Y. Kim Material and Methods: retrospective analysis was performed on 165 patients with locally advanced thyroid papillary carcinoma (T4) or cervical lymph node involvement (N1b), who were treated between 2002 and 2011. Of these, 32 patients were treated with total thyroidectomy followed by adjuvant external beam radiation therapy and radioactive iodine treatment, and 133 patients were treated with total thyroidectomy followed by radioactive iodine treatment.
Results:
The median follow-up time was 223 months (range, 93 to 421 months). The 10-year disease-free survival and locoregional relapse-free survival rates were significantly better than unirradiated controls. 10-year disease-free survival rates for patients in the radiation therapy and no radiation therapy groups were 84.3% and 56.7%, respectively (p = 0.049). 10-year locoregional relapse-free survival rates for patients in the radiation therapy and no radiation therapy groups were 83.9% and 60.8%, respectively (p = 0.037). The overall survival rate and distant relapse-free survival rate were not different between the two groups. Multivariate analysis showed that adjuvant radiation therapy was an independent prognostic factor for locoregional relapse-free survival (p = 0.044). 
Conclusion

Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, United Kingdom
Purpose or Objective: Highly conformal dose distributions produced by rotational IMRT reliably delivered with daily IGRT raise the possibility that radical chemoIMRT for oropharyngeal carcinoma could be delivered in fewer fractions (#) for certain subgroups. The purpose of this study was to compare two cohorts of patients with oropharyngeal carcinoma treated within a single centre: the first treated with a 20# (4 weeks(wk)) schedule, the second with 25-35# (5-7wk) schedules.
Material and Methods:
Patients undergoing radical chemoIMRT between June 2009 and May 2012 were treated with 55Gy/20# over 25 days to PTV1 with synchronous carboplatin or cetuximab (20# cohort). Similar patients were treated between June 2012 and April 2014 with one of three schedules 64Gy/25# over 32 days, 65Gy/30# over 39 days or 70Gy/35# over 46 days to PTV 1 with synchronous cisplatin or cetuximab (25-35# cohort). The local control (LC) and overall survival (OS) of these two cohorts were compared using the log-rank test.
Results:
The minimum time elapsed from treatment in all patients was 18 months. There were 86 patients in the 20# cohort: median age 58 years; p16+ 60 (70%); T4 28 (33%); N2C/N3 16 (19%). There were 77 patients in the 25-35# cohort: median age 59 years; p16+ 54 (70%); T4 24 (32%); N2C/N3 16 (22%). The 18 month local control in the two cohorts respectively was 86% v. 88% (p= 0.69). The 18 month overall survival was 85% v. 89% (p= 0.41). If the two cohorts were restricted to those patients who were p 16+ve, T1-3, no neo-adjuvant chemotherapy and platinum agent used synchronously the corresponding figures (n= 26 for 20# cohort v. n=38 for 25-35# cohort) for local control were 92% v. 95% (p=0.34) and for overall survival 96% v 100% (p=0.22).
Conclusion:
Although further follow up and late toxicity data is required, the similarity in results seen between the two cohorts in this study warrant the testing of the 20# schedule with synchronous cisplatin in a randomised setting in good prognosis oropharyngeal patients. This similarity in the endpoints studied is evidence against synchronous chemotherapy acting to reduce accelerated repopulation
